6505--Carbamazepine 200MG Tablets

PRE-SOLICITATION NOTICE: The VA National Acquisition Center intends to issue Request for Proposal (RFP) 36E79724R0010 for an unrestrictive procurement for Carbamazepine 200MG Tablets, for the Department of Veterans Affairs (VA), Department of Defense (DOD), Bureau of Prisons (BOP), and Indian Health Service (IHS). The VA will award one contract to the responsible offeror who will be able to provide an uninterrupted source of supply for the contracted items. The contract period will be for one year plus four pre-priced one-year option periods. The contract items will be distributed through the VA s and DOD s respective Pharmaceutical Prime Vendor Programs. Offerors must state the exact name (name that appears on label) by which the drug will be supplied and have an NDC number that is unique to the offeror. Solicitation # 36E79724R0010 will be electronically issued in commercial item format in accordance with FAR Part 12 on or about February 6, 2024, with a tentative closing date of February 20, 2024. The NAICS code for this procurement is 325412. Any future amendments and other miscellaneous documents will be available electronically for download at sam.gov. No paper copies of the solicitation will be available, and no telephone requests for paper copies of the solicitation will be accepted. Interested offerors are advised to continuously check this URL for any changes to this solicitation. All responsible sources may submit an offer that if timely received, will be considered. The point of contact for this procurement is Richard Mahario. Questions can be e-mailed to: Richard.Mahario@va.gov The estimated annual requirements are as follows: ITEM DESCRIPTION PACKAGE SIZE (TABLETS PER BOTTLES) TOTAL ESTIMATED ANNUAL USAGE (BOTTLES) 1 CARBAMAZEPINE 200MG TABLETS 100 7,553 2 CARBAMAZEPINE 200MG TABLETS 1000 9,921 Note: Once awarded, this contract will be mandatory for use of the generic version of Carbamazepine Tablets. Agencies will have the ability to continue to prescribe the branded product Tegretol®, for patients where the provider has determined a generic product is NOT clinically appropriate.